@paulinerichaud.bsky.social
Reposted
📰 - MaaT Pharma in Fierce Biotech!
Proud to see our latest achievement covered in Fierce Biotech with Nick Paul Taylor highlighting our positive Phase 3 results evaluating MaaT013 in treating #GI-aGvHD.
👉 Read the full article here: www.fiercebiotech.com/biotech/maat...
Proud to see our latest achievement covered in Fierce Biotech with Nick Paul Taylor highlighting our positive Phase 3 results evaluating MaaT013 in treating #GI-aGvHD.
👉 Read the full article here: www.fiercebiotech.com/biotech/maat...
January 29, 2025 at 4:33 PM
📰 - MaaT Pharma in Fierce Biotech!
Proud to see our latest achievement covered in Fierce Biotech with Nick Paul Taylor highlighting our positive Phase 3 results evaluating MaaT013 in treating #GI-aGvHD.
👉 Read the full article here: www.fiercebiotech.com/biotech/maat...
Proud to see our latest achievement covered in Fierce Biotech with Nick Paul Taylor highlighting our positive Phase 3 results evaluating MaaT013 in treating #GI-aGvHD.
👉 Read the full article here: www.fiercebiotech.com/biotech/maat...
Reposted
📄 [Press release] – MaaT Pharma Announces Positive Safety Interim Analysis from DSMB for Phase 2b Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT 🩸
👉Read the press release here: www.maatpharma.com/april-8-2025...
#Hematology #Oncology #BloodCancer #Cancer #DSMB #Safety #Phase2
👉Read the press release here: www.maatpharma.com/april-8-2025...
#Hematology #Oncology #BloodCancer #Cancer #DSMB #Safety #Phase2
April 8, 2025 at 5:40 AM
📄 [Press release] – MaaT Pharma Announces Positive Safety Interim Analysis from DSMB for Phase 2b Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT 🩸
👉Read the press release here: www.maatpharma.com/april-8-2025...
#Hematology #Oncology #BloodCancer #Cancer #DSMB #Safety #Phase2
👉Read the press release here: www.maatpharma.com/april-8-2025...
#Hematology #Oncology #BloodCancer #Cancer #DSMB #Safety #Phase2
Reposted
📰 MaaT Pharma in @Le Point!
Proud to be featured in the special issue “Ces projets qui façonnent la santé du futur”, highlighting our pioneering work in restoring gut microbiome functions to support cancer patients.
Newspaper available at newsstands or via this link: www.lepoint.fr/versions-num...
Proud to be featured in the special issue “Ces projets qui façonnent la santé du futur”, highlighting our pioneering work in restoring gut microbiome functions to support cancer patients.
Newspaper available at newsstands or via this link: www.lepoint.fr/versions-num...
April 9, 2025 at 10:05 AM
📰 MaaT Pharma in @Le Point!
Proud to be featured in the special issue “Ces projets qui façonnent la santé du futur”, highlighting our pioneering work in restoring gut microbiome functions to support cancer patients.
Newspaper available at newsstands or via this link: www.lepoint.fr/versions-num...
Proud to be featured in the special issue “Ces projets qui façonnent la santé du futur”, highlighting our pioneering work in restoring gut microbiome functions to support cancer patients.
Newspaper available at newsstands or via this link: www.lepoint.fr/versions-num...
Reposted
📰 MaaT Pharma in OncLive!
Thrilled to see our latest announcement covered by Ashling Wahner, highlighting MaaT033’s safety in allo-HSCT patients and the DSMB’s recommendation to continue the PHOEBUS trial.
You can read the article here: www.onclive.com/view/investi...
Thrilled to see our latest announcement covered by Ashling Wahner, highlighting MaaT033’s safety in allo-HSCT patients and the DSMB’s recommendation to continue the PHOEBUS trial.
You can read the article here: www.onclive.com/view/investi...
Investigational Microbiotherapy MaaT033 Is Safe in Allo-HSCT Recipients
An independent DSMB found MaaT033 to have a favorable safety profile in patients with hematologic malignancies undergoing allo-HSCT in the PHOEBUS trial.
www.onclive.com
April 10, 2025 at 3:57 PM
📰 MaaT Pharma in OncLive!
Thrilled to see our latest announcement covered by Ashling Wahner, highlighting MaaT033’s safety in allo-HSCT patients and the DSMB’s recommendation to continue the PHOEBUS trial.
You can read the article here: www.onclive.com/view/investi...
Thrilled to see our latest announcement covered by Ashling Wahner, highlighting MaaT033’s safety in allo-HSCT patients and the DSMB’s recommendation to continue the PHOEBUS trial.
You can read the article here: www.onclive.com/view/investi...
Reposted
After standard treatments failed to control her graft-versus-host disease, an experimental therapy from French biotech MaaT Pharma, delivered through an early access program, dramatically improved her condition. Two weeks later, Maldzinski was discharged. 2/5
January 8, 2025 at 10:17 PM
After standard treatments failed to control her graft-versus-host disease, an experimental therapy from French biotech MaaT Pharma, delivered through an early access program, dramatically improved her condition. Two weeks later, Maldzinski was discharged. 2/5
Reposted
#ASH24 latest in multiple myeloma, GVHD, NHL, respectively, via @onclive.bsky.social #mmsm #lymsm #gvhd #mmsm www.onclive.com/view/breakin...
Breaking the News in Myeloma, GVHD, and NHL, With Drs Rajkumar, Farhadfar, and Smith
S. Vincent Rajkumar, MD, of Mayo Clinic; Nosha Farhadfar, MD, of Methodist Physician Practices; and Sonali Smith, MD, of University of Chicago Medicine, sit down with Chandler Park, MD, FACP, to discu...
www.onclive.com
December 10, 2024 at 4:48 AM
#ASH24 latest in multiple myeloma, GVHD, NHL, respectively, via @onclive.bsky.social #mmsm #lymsm #gvhd #mmsm www.onclive.com/view/breakin...